Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 686

1.

The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them.

Finn OJ, Khleif SN, Herberman RB.

Cancer Prev Res (Phila). 2015 Nov;8(11):1011-6. doi: 10.1158/1940-6207.CAPR-15-0234. Epub 2015 Sep 9.

2.

Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial.

Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB.

Cancer Immunol Res. 2014 Aug;2(8):720-4. doi: 10.1158/2326-6066.CIR-14-0024. Epub 2014 May 6.

3.

Immunotherapy of cancer via mediation of cytotoxic T lymphocytes by methionine enkephalin (MENK).

Li W, Chen W, Herberman RB, Plotnikoff NP, Youkilis G, Griffin N, Wang E, Lu C, Shan F.

Cancer Lett. 2014 Mar 28;344(2):212-22. doi: 10.1016/j.canlet.2013.10.029. Epub 2013 Nov 26.

PMID:
24291668
4.

Re: Mobile phone use and brain tumors in children and adolescents: a multicenter case-control study.

Morgan LL, Herberman RB, Philips A, Lee Davis D.

J Natl Cancer Inst. 2012 Apr 18;104(8):635-7; author reply 637-8. doi: 10.1093/jnci/djs146. Epub 2012 Apr 5. No abstract available.

PMID:
22491231
5.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, HÃ¥kansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

6.

Exposure limits: the underestimation of absorbed cell phone radiation, especially in children.

Gandhi OP, Morgan LL, de Salles AA, Han YY, Herberman RB, Davis DL.

Electromagn Biol Med. 2012 Mar;31(1):34-51. doi: 10.3109/15368378.2011.622827. Epub 2011 Oct 14. Review.

PMID:
21999884
7.

Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.

Meyskens FL Jr, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E; C-Change Chemoprevention Clinical Trials and Biomarkers Subcommittee.

Cancer Prev Res (Phila). 2011 Mar;4(3):311-23. doi: 10.1158/1940-6207.CAPR-09-0014.

8.

Sheddase activity of tumor necrosis factor-alpha converting enzyme is increased and prognostically valuable in head and neck cancer.

Ge L, Baskic D, Basse P, Vujanovic L, Unlu S, Yoneyama T, Vujanovic A, Han J, Bankovic D, Szczepanski MJ, Hunt JL, Herberman RB, Gollin SM, Ferris RL, Whiteside TL, Myers EN, Vujanovic NL.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2913-22. doi: 10.1158/1055-9965.EPI-08-0898. Epub 2009 Oct 20.

9.

Biological significance of prolactin in gynecologic cancers.

Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE.

Cancer Res. 2009 Jun 15;69(12):5226-33. doi: 10.1158/0008-5472.CAN-08-4652. Epub 2009 Jun 2.

10.

Novel method for benchmarking recruitment of African American cancer patients to clinical therapeutic trials.

Morgenlander KH, Winters SB, Lin CJ, Robertson LB, Heron DE, Herberman RB.

J Clin Oncol. 2008 Nov 1;26(31):5074-7. doi: 10.1200/JCO.2008.17.3039. Epub 2008 Sep 22.

11.

Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma.

Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, Herberman RB, Zou W.

Cancer Res. 2007 Aug 1;67(15):7487-94.

12.

NK cells in cancer immunotherapy: three decades of discovery.

Boyiadzis M, Foon KA, Herberman RB.

Discov Med. 2006 Dec;6(36):243-8.

13.

A novel cross-disciplinary multi-institute approach to translational cancer research: lessons learned from Pennsylvania Cancer Alliance Bioinformatics Consortium (PCABC).

Patel AA, Gilbertson JR, Showe LC, London JW, Ross E, Ochs MF, Carver J, Lazarus A, Parwani AV, Dhir R, Beck JR, Liebman M, Garcia FU, Prichard J, Wilkerson M, Herberman RB, Becich MJ; PCABC.

Cancer Inform. 2007 Jun 8;3:255-74.

14.
15.

Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.

Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM.

J Immunol. 2006 Aug 15;177(4):2717-27.

16.

IL-18-induced CD83+CCR7+ NK helper cells.

Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB, Kalinski P.

J Exp Med. 2005 Oct 3;202(7):941-53.

17.

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB.

Expert Opin Biol Ther. 2005 Oct;5(10):1303-15. Review.

PMID:
16197336
18.

Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.

Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7.

19.

Translation of scientific insights to benefit patients with cancer.

Herberman RB.

Cancer Biol Ther. 2004 Aug;3(8):778-81. Epub 2004 Aug 15. No abstract available.

PMID:
15492496
20.

Immunologic aspects of chronic fatigue syndrome. Report on a Research Symposium convened by The CFIDS Association of America and co-sponsored by the US Centers for Disease Control and Prevention and the National Institutes of Health.

Gerrity TR, Papanicolaou DA, Amsterdam JD, Bingham S, Grossman A, Hedrick T, Herberman RB, Krueger G, Levine S, Mohagheghpour N, Moore RC, Oleske J, Snell CR; CFIDS Association of America.

Neuroimmunomodulation. 2004;11(6):351-7. Review.

PMID:
15467349
21.

A novel epitope of N-CAM defines precursors of human adherent NK cells.

Li S, Xu J, Makarenkova VP, Tjandrawan T, Vakkila J, Reichert T, Gooding W, Lagenaur CF, Achim CL, Chambers WH, Herberman RB, Whiteside TL, Vujanovic NL.

J Leukoc Biol. 2004 Dec;76(6):1187-99. Epub 2004 Sep 8.

PMID:
15356097
22.

Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases.

Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC, Goldfarb RH, Herberman RB, Basse PH.

Int J Cancer. 2003 Jul 1;105(4):512-9.

23.

Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.

Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Herberman RB, Lotze MT, Shurin MR.

J Exp Ther Oncol. 2002 Nov-Dec;2(6):337-49.

PMID:
12440225
24.

Cancer immunotherapy with natural killer cells.

Herberman RB.

Semin Oncol. 2002 Jun;29(3 Suppl 7):27-30. Review.

PMID:
12068385
25.

Cancer immunotherapy with interleukin-2-activated natural killer cells.

Basse PH, Whiteside TL, Herberman RB.

Mol Biotechnol. 2002 Jun;21(2):161-70.

PMID:
12059115
26.

Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells.

Ernst LK, Metes D, Herberman RB, Morel PA.

J Mol Med (Berl). 2002 Apr;80(4):248-57. Epub 2001 Nov 22.

PMID:
11976734
27.

Therapeutic activity of NK cells against tumors.

Basse PH, Whiteside TL, Chambers W, Herberman RB.

Int Rev Immunol. 2001 Jun;20(3-4):439-501. Review.

PMID:
11878512
28.

Ig-binding receptors on human NK cells as effector and regulatory surface molecules.

Sulica A, Morel P, Metes D, Herberman RB.

Int Rev Immunol. 2001 Jun;20(3-4):371-414. Review.

PMID:
11878510
29.

Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay.

Wahlberg BJ, Burholt DR, Kornblith P, Richards TJ, Bruffsky A, Herberman RB, Vujanovic NL.

J Immunol Methods. 2001 Jul 1;253(1-2):69-81.

PMID:
11384670
30.

Andrei Sulica, MD, 1938-2000.

Herberman RB.

Nat Immun. 1998 Sep;16(5-6):176-177.

31.

Role of natural killer cells and T cells in immune surveillance.

Herberman RB.

Leuk Res. 2000 Sep;24(9):775. No abstract available. Erratum in: Leuk Res. 2001 Jan;25(1):101.

PMID:
10978782
32.

Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon.

Walter MR, Bordens R, Nagabhushan TL, Williams BR, Herberman RB, Dinarello CA, Borden EC, Trotta PP, Pestka S, Pfeffer LM.

Cancer Biother Radiopharm. 1998 Jun;13(3):143-54. Review.

PMID:
10850350
33.

Use of activated natural killer cells for tumor immunotherapy in mouse and human.

Basse PH, Whiteside TL, Herberman RB.

Methods Mol Biol. 2000;121:81-94. Review. No abstract available.

PMID:
10818719
34.

Summary of the International Cancer Microenvironment from meeting in Pittsburgh, Pennsylvania on October 3-6, 1999.

Herberman RB, Whiteside TL.

Cancer Res. 2000 Mar 1;60(5):1465-9. No abstract available.

36.

Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells.

Kashii Y, Giorda R, Herberman RB, Whiteside TL, Vujanovic NL.

J Immunol. 1999 Nov 15;163(10):5358-66.

37.

Ligand binding specificities and signal transduction pathways of Fc gamma receptor IIc isoforms: the CD32 isoforms expressed by human NK cells.

Metes D, Manciulea M, Pretrusca D, Rabinowich H, Ernst LK, Popescu I, Calugaru A, Sulica A, Chambers WH, Herberman RB, Morel PA.

Eur J Immunol. 1999 Sep;29(9):2842-52.

38.

Characterization of the stage in natural killer cell development in 14.5-day mouse fetal liver using adult bone marrow stroma.

Lu J, Patrene KD, Appasamy PM, Herberman RB, Boggs SS.

Exp Hematol. 1999 Jun;27(6):1046-56.

PMID:
10378894
39.

Expression of murine CD34 by fetal liver NK cell progenitors.

Lu J, Patrene KD, Herberman RB, Boggs SS.

Exp Hematol. 1999 Feb;27(2):272-81.

PMID:
10029167
40.

Dysfunction of natural killer activity in a family with chronic fatigue syndrome.

Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herberman RB.

Clin Immunol Immunopathol. 1998 Jul;88(1):96-104.

PMID:
9683556
41.

Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.

Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S.

Cancer Res. 1998 Jun 15;58(12):2489-99. Review.

42.

Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.

Nagashima S, Mailliard R, Kashii Y, Reichert TE, Herberman RB, Robbins P, Whiteside TL.

Blood. 1998 May 15;91(10):3850-61.

43.

Natural killer cells and tumor therapy.

Whiteside TL, Vujanovic NL, Herberman RB.

Curr Top Microbiol Immunol. 1998;230:221-44. Review.

PMID:
9586358
44.

Conservation of total T-cell counts during HIV infection: alternative hypotheses and implications.

Grossman Z, Herberman RB, Vatnik N, Intrator N.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 15;17(5):450-7. Review.

PMID:
9562048
45.

Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene.

Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA.

Blood. 1998 Apr 1;91(7):2369-80.

46.

Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion.

Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, Kowal CD, Kunschner AJ, Baldisseri M, Kirkwood JM, Herberman RB.

J Clin Oncol. 1997 Nov;15(11):3399-407.

PMID:
9363872
47.

Effect of alpha-interferons on immune function.

Herberman RB.

Semin Oncol. 1997 Jun;24(3 Suppl 9):S9-78-S9-80. Review.

PMID:
9208876
48.

Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma.

Kirkwood JM, Wilson J, Whiteside TL, Donnelly S, Herberman RB.

Cancer Immunol Immunother. 1997 May;44(3):137-49.

PMID:
9191873
49.
50.

Methionine enkephalin: a new cytokine--human studies.

Plotnikoff NP, Faith RE, Murgo AJ, Herberman RB, Good RA.

Clin Immunol Immunopathol. 1997 Feb;82(2):93-101. Review.

PMID:
9000477

Supplemental Content

Loading ...
Support Center